← Back to Search

Other

QN-302 for Advanced Cancer

Phase 1

Recruiting

Research Sponsored by Qualigen Theraputics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with histologically confirmed locally advanced or metastatic solid carcinomas, who have had tumor progression after receiving all standard of care therapies or for which there is no approved therapy

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Study Summary

This trial tests a new drug to see if it can help people with advanced cancer. It is given as an IV once a week for 3 weeks in a 4 week cycle to see how it affects the body and if it is safe.

Who is the study for?

This trial is for patients with advanced or metastatic solid tumors who have seen their cancer progress after all standard treatments, or when no approved therapy exists. They must have a disease that can be measured by RECIST 1.1 criteria.Check my eligibility

What is being tested?

The trial is testing QN-302, a new drug given through an IV once a week for three weeks in every four-week cycle. It aims to understand the drug's effects on the body (PD) and how the body processes it (PK), as well as its safety.See study design

What are the potential side effects?

While specific side effects of QN-302 are not listed, common ones for cancer drugs include fatigue, nausea, infusion reactions, organ inflammation, blood disorders and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has spread and worsened after all standard treatments.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determine MTD

Establish RP2D

Trial Design

2Treatment groups

Experimental Treatment

Group I: Cohort 2Experimental Treatment1 Intervention

2nd cohort in dose escalation

Group II: Cohort 1Experimental Treatment1 Intervention

Starting dose in dose escalation

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Qualigen Theraputics, Inc.Lead Sponsor

Translational Drug DevelopmentOTHER

18 Previous Clinical Trials

958 Total Patients Enrolled

Tariq Arschad, MDStudy DirectorQualigen Theraputics, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there research centers in North America conducting this investigation?

"This clinical trial is open to patients registered at Yale in New Haven, START Midwest in Grand Rapids, MD Anderson Cancer Center in Houston, and another 4 sites."

Answered by AI

How hazardous are the effects of Cohort 1 on individuals' health?

"As this is an early-stage trial, our team at Power has rated Cohort 1's safety on a scale of 1 to 3 as a conservative score of 1 due to the limited data available regarding efficacy and safety."

Answered by AI

Is enrollment for this clinical research still available at the present time?

"The clinicaltrials.gov database has revealed that this research, which was initially posted on the 12th of October 2023, is no longer recruiting participants. However, currently there are 2,761 other trials actively enrolling patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

2023. "Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06086522.